Skip to main content

Small but Important Differences Seen Between Rosuvastatin, Atorvastatin

Medically reviewed by Carmen Pope, BPharm. Last updated on Oct 30, 2024.

By Lori Solomon HealthDay Reporter

WEDNESDAY, Oct. 30, 2024 -- There are small but important differences in risk for some clinical outcomes associated with rosuvastatin and atorvastatin, according to a study published online Oct. 29 in Annals of Internal Medicine.

Shiyu Zhou, M.D., from Southern Medical University in Guangzhou, China, and colleagues compared the real-world effectiveness and safety of rosuvastatin and atorvastatin. The analysis included 285,680 eligible participants identified from the China Renal Data System (CRDS) and U.K. Biobank (UKB) databases.

The researchers found that six-year all-cause mortality was lower for rosuvastatin than for atorvastatin (2.57 versus 2.83 per 100 person-years in the CRDS database and 0.66 versus 0.90 per 100 person-years in the UKB database). Differences in cumulative incidence were −1.03 percent in the CRDS database and −1.38 percent in the UKB database. Rosuvastatin conferred lower risks for the secondary outcomes of major adverse cardiovascular events and major adverse liver outcomes. The risk for developing type 2 diabetes mellitus was higher in the UKB database with rosuvastatin, but the two medications carried similar risks for developing chronic kidney disease and other statin-related adverse effects.

"Rosuvastatin might be associated with cardiovascular and mortality benefits that need to be weighed against the risk for development of type 2 diabetes mellitus," the authors write.

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.

Posted October 2024

Read this next

Metabolic Dysfunction-Linked Steatotic Liver Disease Tied to Increased Preterm Birth Risk

TUESDAY, May 20, 2025 -- Metabolic dysfunction-associated steatotic liver disease (MASLD) in pregnant women is a risk factor for preterm birth, according to a study published...

GLP-1 Receptor Agonists Not Linked to Increased Risk of Psychiatric Adverse Events, Depression

MONDAY, May 19, 2025 -- For patients with overweight/obesity and/or diabetes, glucagon-like peptide 1 receptor agonist (GLP-1 RA) treatment is not associated with an increased...

Preoperative SGLT2 Inhibitor Users Have Increased Risk for Postoperative Euglycemic Ketoacidosis

TUESDAY, May 13, 2025 -- Patients using sodium-glucose cotransporter 2 inhibitors (SGLT2i) preoperatively have a slightly increased risk for postoperative euglycemic ketoacidosis...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.